Clinical Trial Subgroup Data: How Much Is Enough?
Executive Summary
FDA could use epidemiology data on disease prevalence or insurance claims data to determine acceptable subgroup sizes, advocates say.
You may also be interested in...
Should US FDA Refuse Approval If Women Under-Represented In Clinical Trials?
Idea suggested during 'Great Debate,' but agency official says no adlibbing is allowed in the regulations.
FDA Carrots And Sticks Are Best Way To Get Subgroup Data, Advocates Say
Stakeholders tell FDA it should force sponsors to recruit more diverse populations for its clinical trials by refusing to approve applications with inadequate data or expediting those with the necessary information.
PhRMA’s “I’m In” Campaign Looks To Connect Minorities To Studies
Extension of the Clinical Trial Engagement Network is aimed at increased diversity in clinical trials, which is becoming increasingly important as more drugs are targeted at specific groups.